AI创造分子获提名“医药界诺贝尔” 中国药企孵化胃癌新药开辟新路径

Core Insights - Signet Therapeutics, a company incubated by Shenzhen Jingtai Technology, has been nominated for the 2025 Prix Galien USA, marking it as the only Chinese biopharmaceutical company nominated for the "Best Biotechnology Product Award" with its targeted drug SIGX1094R for diffuse gastric cancer [1][2] - The nomination highlights the integration of AI and organoid technology in drug development, representing a paradigm shift in new drug research and development [1] Company Developments - SIGX1094R has received orphan drug designation (ODD) and fast track designation (FTD) from the FDA and is currently undergoing Phase I clinical trials at Peking University Cancer Hospital [2] - The drug is the first dual-target inhibitor (FAK/SRC) for diffuse gastric cancer to enter clinical stages, developed using organoid models and AI technology [1][2] - Jingtai Technology's proprietary Xpose algorithm and XFEP free energy perturbation technology enabled the completion of preclinical candidate compound (PCC) development in just six months, reducing the traditional development cycle by over 60% [1] Industry Context - The Prix Galien, established in 1970 and often referred to as the "Nobel Prize of Medicine," is considered the highest honor in the pharmaceutical industry, with a 2025 review committee comprising 11 members, including three Nobel laureates [2] - In 2023, Jingtai Technology signed a $250 million collaboration with Eli Lilly for AI and robotic drug discovery, setting a record for the highest single pipeline AI drug discovery collaboration in China [2] - In August 2025, Jingtai Technology entered into a partnership with innovative biopharmaceutical company DoveTree for AI drug development, with a total order value of approximately HKD 47 billion ($5.99 billion), further establishing its leadership in AI drug development [2]